AstraZeneca and Sanofi Block Access to 340B Contract Pharmacy Pricing, Novartis Does Not (UPDATED)

AstraZeneca and Sanofi Block Access to 340B Contract Pharmacy Pricing, Novartis Does Not (UPDATED)

(UPDATED Friday Oct. 2, 2020, 4:30 p.m. EDT)

Congressman Grills Novartis Executive About Steps to Limit 340B Discounts

A Republican U.S. congressman from rural central Pennsylvania

Read More »

The Calm Before the 340B Storm?

A message from 340B Report Publisher and CEO Ted Slafsky: We are pleased to have a sponsored content piece today by Equiscript CEO Michael Burkhold. I encourage you to read it. We will have more information about 340B Report

Read More »

Only 30 Providers Are Supplying Merck with Requested 340B Claims Data

Only 30 Providers Are Supplying Merck with Requested 340B Claims Data

Only 30—less than 1 percent—of the 340B covered entities that drug manufacturer Merck wrote to this summer seeking their contract pharmacy claims data are sharing their data with Merck

Read More »

Breaking News

BREAKING: Novartis Says It’s Weighing Whether to Start Cutting Off 340B Contract Pharmacy Discounts on Oct. 1. Sanofi Says it Will. (Update 1)

Novartis Says It’s Weighing Whether to Start Cutting Off 340B Contract Pharmacy Discounts on Oct. 1. Sanofi Says it Will.

(Update 1, Friday Sept. 25, 1:00 p.m. EDT—Merck is “considering any next steps in our effort to ensure compliance with

Read More »

Is Novartis Backing Off its Oct. 1 Deadline for 340B Covered Entities? (Update 2)

Note from 340B Report Publisher and CEO Ted Slafsky: I look forward to moderating a panel on the latest 340B developments, President Trump’s drug pricing executive orders, as well as the upcoming elections this Tuesday, Sept. 29 at 12:00

Read More »

Breaking News

BREAKING: HHS Top Lawyer Tells Lilly, Don’t Assume We Endorse Your 340B Policy

HHS Top Lawyer Tells Lilly, Don’t Assume We Endorse Your 340B Policy

The top lawyer at the U.S. Health and Human Services (HHS) department told drug manufacturer Eli Lilly and Co. in a letter dated Sept. 21 and made

Read More »

HHS Inundated with Concerns About Pharma’s and Administration’s 340B Actions

Bipartisan Group of 28 U.S. Senators Ask Azar to Halt Recent Pharma 340B Actions Immediately

Twenty eight U.S. senators—15 Democrats, 12 Republicans, and an independent—wrote to U.S. Health and Human Services (HHS) Secretary Alex Azar today to

Read More »

Breaking News

BREAKING: 22 U.S. Senate Democrats Want Answers from PhRMA About its Members’ 340B Actions

22 U.S. Senate Democrats Want Answers from PhRMA About its Members’ 340B Actions

Twenty-two Democratic U.S. senators asked Pharmaceutical Research and Manufacturers of America (PhRMA) today to inform them by no later than Sept. 29 “regarding steps being taken by

Read More »

In Partisan U.S. House, Consensus Emerges Over Manufacturer 340B Actions

Note from Publisher and CEO Ted Slafsky: I encourage you to read today’s sponsored content article from 340B Report sponsor Trellis Rx about a Sept. 22 panel discussion on recent manufacturer actions in the contract pharmacy space as well as mitigation

Read More »

Breaking News

BREAKING: More than Half of the U.S. House Asks Azar to Address Drug Makers’ 340B Actions Immediately

More than Half of the U.S. House Asks Azar to Address Drug Makers’ 340B Actions Immediately

More than half of the U.S. House today told U.S. Health and Human Services (HHS) Secretary Alex Azar “it is imperative that immediate action

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live